case_images: PMC11129569_01
case_images: Chest and abdomen computed tomography and pelvic magnetic resonance imaging. (a). Left supraclavicular lymph node enlargement, diameter 1.8 x 1.2 cm. (b), (c). Left lobe of liver, low-density foci in hilar area, mild enhancement, unclear boundary with pancreatic head, hepatogastric space, abdominal cavity, retroperitoneal lymph node enlargement. (d), (e). Double lung patches, masses, and nodules of primary lung tumors and mediastinal lymph node enlargement. (f). Nodular abnormalities in the left posterior and anterior edges of the prostate, involving both sides of seminal vesicles.
case_images: 10.1177_2050313X241252371-fig1.jpg
case_images: PMC11129569_01_10.1177_2050313X241252371-fig1.jpg
case_images: fig1-2050313X241252371
case_images: TPSA 81.14 ng/ml, FPSA 7.363 ng/ml, FPSA/TPSA 0.09, NSE 17.76 ng/ml, and CYFRA21-1 10.76 ng/ml. Chest and abdomen computed tomography (CT) and pelvic magnetic resonance imaging results are shown in Figure 1. Tissue biopsy was performed in lung-, liver-, and prostate space-occupying positions, and the pathological results are shown in Figure 2.
case_images: Pathological results of needle biopsy. (a). Liver mass biopsy pathology: adenocarcinoma indicative of intrahepatic cholangiocarcinoma combined with medical history and immunohistochemistry. Immunohistochemistry: hepatocyte (-), GPC-3 (-), CK19 (+), CK7 (+), TTF-1 (-), NapsinA (-). (b). Pathology of puncture of prostatic space-occupying lesions: (1-9 prostate punctures) acinar adenocarcinoma; overall Gleason grading score: 3 + 4 = 7 points; immunohistochemical results: P504S (+), P63 (basal cell-). (c). Pathology of pulmonary puncture biopsy: mucinous adenocarcinoma, combined with morphological and immunohistochemical results, consistent with the primary lung. Immunohistochemistry: CK20 (-), CK7 (+), CK19 (+), NapsinA (+), TTF-1 (+), Villin (-), SATB2 (-), PSA (-).
case_images: 10.1177_2050313X241252371-fig2.jpg
case_images: PMC11129569_01_10.1177_2050313X241252371-fig2.jpg
case_images: fig2-2050313X241252371
case_images: TPSA 81.14 ng/ml, FPSA 7.363 ng/ml, FPSA/TPSA 0.09, NSE 17.76 ng/ml, and CYFRA21-1 10.76 ng/ml. Chest and abdomen computed tomography (CT) and pelvic magnetic resonance imaging results are shown in Figure 1. Tissue biopsy was performed in lung-, liver-, and prostate space-occupying positions, and the pathological results are shown in Figure 2.
case_images: Results of lung cancer testing of nine genes and whole-exome sequencing detection of prostate cancer and intrahepatic cholangiocarcinoma. (a) The gene mutations in lung cancer, intrahepatic cholangiocarcinoma, and prostate cancer are subjected to an intersection assessment; (b). The predicted neoantigen peptides are subjected to an intersection assessment.
case_images: 10.1177_2050313X241252371-fig3.jpg
case_images: PMC11129569_01_10.1177_2050313X241252371-fig3.jpg
case_images: fig3-2050313X241252371
case_images: Technologies (IDT) xGEN Exome panel consists of 429,826 biotinylated probes designed to capture 19,396 genes (a 39 Mb region). Then, 20 same mutation sites in 16 genes, such as KMT2C, ANKS1A, ATAD3B, CABLES1, CHIT1, FAM155A, LCORL, MAFA, MKRN1, MUC17, MUC6, PRSS3, RBMX, RETSAT, SREBF2, and UBXN11 (Figure 3(a), Supplemental material Table S1) were found in both tissues. Besides, we selected four same peptides from the both tissues (Figure 3(b), Supplemental material Table S2).
case_images: Computed tomography review results. (a) Progression of lung lesions; (b) progression of brain metastases; (c) progression of liver lesions.
case_images: 10.1177_2050313X241252371-fig4.jpg
case_images: PMC11129569_01_10.1177_2050313X241252371-fig4.jpg
case_images: fig4-2050313X241252371
case_images: Re-examination of CT after 2 months revealed the progress of lung and liver lesions and brain metastases (Figure 4).